Author:
Meerpohl Joerg J,Antes Gerd,Rücker Gerta,Fleeman Nigel,Niemeyer Charlotte M,Bassler Dirk
Reference93 articles.
1. Cappellini MD Vichinsky E Ford JM Rabault B Porter J Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) <= 1000 ng/mL in long-term studies Blood 2007 16B
2. Cappellini MD Vichinsky E Galanello R Piga A Williamson P Porter JB Long-term treatment with deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias Blood 2007 816A
3. Piga A Vichinsky E Forni GL Kilinc Y Maseruka H Kattamis A Long-term efficacy and safety with deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, in pediatric patients Blood 2007 815A
4. Vichinsky E Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract] 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA 2006 Abstract no: 174
5. Vichinsky E Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract] 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006 Abstract no: 175
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献